CardioVascular and Interventional Radiology (CVIR) is the official journal of
the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Founded in 1978 by Professors Herbert L. Abrams and Eberhard Zeitler,
CVIR is the longest-running journal in the field of vascular and interventional radiology.
Read the September issue, which includes a special section dedicated to oncology:
• what IRs need to know about IO
• oncology-specific procedures on targeted organs
Prof. Thierry de Baère
Both articles on the first data release presented by Michael Dake and Konstantinos Donas at the FIRST@CIRSE session at CIRSE 2019 are now available to read for free in CVIR online.
Thank you to all who participated at this year's workshop at CIRSE 2019!
Klaus Hausegger (Editor-in-Chief) and Raman Uberoi (Deputy Editor-in-Chief) talked about the best peer-review practices for CVIR, as well as how to prepare reviews that will benefit the scientific community.
Congratulations to the 2019 CVIR Award Winners!
A big thank you to all authors for making CVIR their preferred journal and a big thank you to all reviewers for their tremendous support!
Read all winning articles by clicking
The 2018 Journal Citation Reports have been released, announcing CVIR's new impact factor (IF): 1.928
The IF is one of the factors that researchers consider in deciding where to publish their research. Journal reputation, readership and community, as well as speed of publication are also among these factors.
CVIR is pleased to announce that it has introduced a template for reviewers in Editorial Manager.
The editors' aim with this new initiative is to improve the overall quality of review reports and to make the assessment of manuscripts easier.
This year it is our pleasure to award the CVIR Editors’ Medal 2019 to the author group by MR Meijerink & RS Puijk et al.for their publication on the topic of thermal ablation and chemotherapy for the treatment of small unresectable colorectal liver metastases.
Palliative treatment or best supportive care for octogenarians? This study of 86 octogenarian patients with HCC that received TACE reveals overall median survival time of 38.3 months and a 3 year survival of 61.1% supporting best treatment; performance status appears to be a prognostic significant factor though and needs to be taken into account!